Caring Ambassadors Hepatitis C Program Newsletter

www.HepCChallenge.org

June 2010

Clinical Trials, Cohort Studies, Pilot Studies

Establishment of a successful assessment and treatment service for Australian prison inmates with chronic hepatitis C. Boonwaat L, Haber PS, Levy MH, Lloyd AR. Med J Aust. 2010 May 3;192(9):496-500.

http://www.ncbi.nlm.nih.gov/pubmed/20438418

Digital quantification is more precise than traditional semiquantitation of hepatic steatosis: correlation with fibrosis in 220 treatment-naïve patients with chronic hepatitis C. Rawlins SR, El-Zammar O, Zinkievich JM, Newman N, Levine RA. Dig Dis Sci. 2010 May 12. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20458626

Non-invasive assessment of liver fibrosis progression in hepatitis C patients retreated for 96 weeks with antiviral therapy: a randomized study. Zarski JP, Sturm N, Desmorat H, et al. Liver Int. 2010 May 21. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20492512

Enhanced adherence to HCV therapy with higher dose ribavirin formulation: final analyses from the ADHERE registry. Alam I, Stainbrook T, Cecil B, Kistler KD. Aliment Pharmacol Ther. 2010 May 25. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20500732

Identifying HCV genotype 1 patients at risk of relapse. Deschênes M, Bain VG, Lee SS, et al. Eur J Gastroenterol Hepatol. 2010 May;22(5):546-51.

http://www.ncbi.nlm.nih.gov/pubmed/20216320

Do steatosis and steatohepatitis impact on sustained virological response (SVR) rates in patients receiving pegylated interferon and ribavirin for chronic hepatitis C infection?

Cross TJ, Quaglia A, Nolan J, Hughes S, Harrison PM. J Med Virol. 2010 May;82(6):958-64.

http://www.ncbi.nlm.nih.gov/pubmed/20419809

Hepatitis C virus infection, age, and hispanic ethnicity increase mortality from liver cancer in the United States. Younossi ZM, Stepanova M. Clin Gastroenterol Hepatol. 2010 May 17. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20435163

Intermediate hepatobiliary cells predict an increased risk of hepatocarcinogenesis in patients with hepatitis c virus-related cirrhosis. Ziol M, Nault JC, Aout M, et al. Gastroenterology. 2010 May 19. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20399781

Prognostic factors associated with hepatitis C disease: a case-control study utilizing U.S. multiple-cause-of-death data. Wise M, Finelli L, Sorvillo F. Public Health Rep. 2010 May-Jun;125(3):414-22.

http://www.ncbi.nlm.nih.gov/pubmed/20433036

Efficacy and safety of pegylated IFN alfa 2b alone or in combination with ribavirin in thalassemia major with chronic hepatitis C. Sood A, Sobti P, Midha V, et al. Indian J Gastroenterol. 2010 Mar;29(2):62-5. Epub 2010 May 5.

http://www.ncbi.nlm.nih.gov/pubmed/20443101

Rituximab plus Peg-Interferon {alpha} /ribavirin compared to Peg- Interferon {alpha} /ribavirin in Hepatitis C related mixed cryoglobulinemia. Saadoun D, Resche Rigon M, Sene D, et al. Blood. 2010 May 3. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20439619

Thyroid function outcomes following pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Tran HA, Reeves GE, Ianna EA, Leembruggen N. Endocr Pract. 2010 May 3:1-16. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20439240

Prevalence and impact of manic traits in depressed patients initiating interferon therapy for chronic hepatitis c infection. Lim C, Olson J, Zaman A, Phelps J, Ingram KD. J Clin Gastroenterol. 2010 May 20. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20495465

Impact of depressive symptoms and their treatment on completing antiviral treatment in patients with chronic hepatitis C. Liu SS, Schneekloth TD, Talwalkar JA, et al. J Clin Gastroenterol. 2010 May 20. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20495464

Prevalence and impact of occult hepatitis B infection in chronic hepatitis C patients treated with pegylated interferon and ribavirin. Levast M, Larrat S, Thelu MA, et al. J Med Virol. 2010 May;82(5):747-54.

http://www.ncbi.nlm.nih.gov/pubmed/20336715

HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Yu ML, Lee CM, Chuang WL, et al. J Infect Dis. 2010 May 18. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20482252

Basic and Applied Science, Pre-Clinical Studies

Large-scale candidate gene analysis of spontaneous clearance of hepatitis C virus. Mosbruger TL, Duggal P, Goedert JJ, et al. J Infect Dis. 2010 May 1;201(9):1371-80.

http://www.ncbi.nlm.nih.gov/pubmed/20331378

La protein required for internal ribosome entry site-directed translation is a potential therapeutic target for hepatitis C virus replication. Shirasaki T, Honda M, Mizuno H, et al. J Infect Dis. 2010 May 24. [Epub ahead of print]

Inhibition of hepatitis C virus replication by single-stranded RNA structural mimics. Smolic R, Smolic M, Andorfer JH, Wu CH, Smith RM, Wu GY. World J Gastroenterol. 2010 May 7;16(17):2100-8.

http://www.ncbi.nlm.nih.gov/pubmed/20440850

Regulation of PKR by HCV IRES RNA: Importance of Domain II and NS5A. Toroney R, Nallagatla SR, Boyer JA, Cameron CE, Bevilacqua PC. J Mol Biol. 2010 May 4. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20447405

HCV NS5A activates the mammalian target of rapamycin (mTOR) pathway contributing to cell survival via disrupting the interaction between FK506-binding protein 38 (FKBP38) and mTOR. Lu P, Liang D, Tong W, Li J, Yuan Z. J Biol Chem. 2010 May 3. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20439463

HIV/HCV Coinfection

Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. Rallón NI, Naggie S, Benito JM, et al. AIDS. 2010 May 15;24(8):F23-9.

http://www.ncbi.nlm.nih.gov/pubmed/20389235

Hepatitis C seropositivity is not a risk factor for sensory neuropathy among patients with HIV. Cherry CL, Affandi JS, Brew BJ, et al. Neurology. 2010 May 11;74(19):1538-42.

http://www.ncbi.nlm.nih.gov/pubmed/20458071

Coinfection with hepatitis C virus, oxidative stress and antioxidant status in HIV-positive drug users in Miami. Baum MK, Sales S, Jayaweera DT,et al. HIV Med. 2010 May 23. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20500231

Impact of highly active antiretroviral therapy on hepatitis C virus protease quasispecies diversity in HIV co-infected patients. Winters MA, Chary A, Eison R, Asmuth D, Holodniy M. J Med Virol. 2010 May;82(5):791-8.

http://www.ncbi.nlm.nih.gov/pubmed/20336744

Stronger hepatitis C virus-specific CD8(+) T-cell responses in HIV coinfection. Barrett L, Gallant M, Howley C, Ian Bowmer M, Hirsch G, Peltekian K, Grant M. J Viral Hepat. 2010 May 20. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20497309

Combined use of aspartate aminotransferase, platelet count and matrix metalloproteinase 2 measurements to predict liver fibrosis in HIV/hepatitis C virus-coinfected patients. Macías J, Mira JA, Gilabert I, et al. HIV Med. 2010 May 17. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20497249

Mitochondrial toxicity is associated with virological response in patients with HIV and hepatitis C Virus coinfection treated with ribavirin and highly active antiretroviral therapy. Reiberger T, Kosi L, Maresch J, et al. J Infect Dis. 2010 May 20. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20486858

Impact of hepatitis C viral replication on CD4+ T-lymphocyte progression in HIV-HCV coinfection before and after antiretroviral therapy. Potter M, Odueyungbo A, Yang H, et al. AIDS. 2010 May 14. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/sites/entrez

Complementary and Alternative Medicine

Nutrigenomics Therapy of Hepatisis C Virus Hepatosteatosis. Qing L, Bengmark S, Shen Q. BMC Gastroenterol. 2010 May 20;10(1):49. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20487553

Epidemiology, Diagnostics, and Miscellaneous Works

Hepatocellular carcinoma - United States, 2001-2006. Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2010 May 7;59(17):517-20.

http://www.ncbi.nlm.nih.gov/pubmed/20448528

Challenge pools of hepatitis C virus genotypes 1-6 prototype strains: replication fitness and pathogenicity in chimpanzees and human liver-chimeric mouse models.

Bukh J, Meuleman P, Tellier R, et al. J Infect Dis. 2010 May 1;201(9):1381-9.

http://www.ncbi.nlm.nih.gov/pubmed/20353362

Prospective follow-up of patients with acute hepatitis C virus infection in Brazil. Lewis- Ximenez LL, Lauer GM, Schulze Zur Wiesch J, et al. Clin Infect Dis. 2010 May 1;50(9):1222-30.

http://www.ncbi.nlm.nih.gov/pubmed/20235831

Hepatitis C testing practices and prevalence in a high-risk urban ambulatory care setting.

Southern WN, Drainoni ML, Smith BD, et al. J Viral Hepat. 2010 May 20. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20497311

Hepatitis C virus risk behaviors within the partnerships of young injecting drug users.

Hahn JA, Evans JL, Davidson PJ, Lum PJ, Page K. Addiction. 2010 May 14. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20491725

Socio-behavioral and geographic correlates of prevalent hepatitis C virus infection among young injection drug users in metropolitan Baltimore and Chicago. Boodram B, Golub ET, Ouellet LJ. Drug Alcohol Depend. 2010 May 14. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20472373